메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Roshni D. Kalachand (Royal College of Surgeons in Ireland Beaumont Hospital) Ciaran O’Riain (Central Pathology Laboratory St. James’s Hospital) Sinead Toomey (Royal College of Surgeons in Ireland Beaumont Hospital) Aoife Carr (Royal College of Surgeons in Ireland Beaumont Hospital) Kirsten M. Timms (Myriad Genetics Inc.) Sharon O’Toole (Trinity Centre for Health Sciences St. James’s Hospital) Stephen Madden (Royal College of Surgeons in Ireland Beaux Lane House) Mark Bates (Trinity Centre for Health Sciences St. James’s Hospital) John J. O’Leary (Central Pathology Laboratory St. James’s Hospital) Noreen Gleeson (Trinity Centre for Health Sciences St. James’s Hospital) Dearbhaile O’Donnell (Trinity College Dublin St. James’s Hospital) Liam Grogan (Beaumont Hospital) Oscar Breathnach (Beaumont Hospital) Angela Farrelly (Royal College of Surgeons in Ireland Beaumont Hospital) Britta Stordal (Middlesex University) Bryan T. Hennessy (Royal College of Surgeons in Ireland Beaumont Hospital)
저널정보
대한산부인과학회 Obstetrics & Gynecology Science Obstetrics & Gynecology Science 제63권 제5호
발행연도
2020.1
수록면
643 - 654 (12page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
ObjectiveThe therapeutic benefits of poly(ADP-ribose) polymerase inhibitors highlight the need to evaluate BRCA1/2 defectsin tubal/ovarian cancer (OC). We sought to determine the pattern and disease characteristics associated with tumorBRCA1/2 mutations and BRCA1 methylation in women with OC. MethodsWe obtained 111 OC specimens from 2 university hospitals and assessed BRCA1/2 mutations and BRCA1 methylationin tumor DNA. The frequency and pattern of BRCA1/2 defects were examined. Associations between patient/diseasecharacteristics and BRCA1/2 defects were ascertained (Fisher’s exact test). Platinum-free interval (PFI), progression-free survival (PFS), and overall survival (OS) based on the underlying BRCA1/2 defect were determined (Kaplan-Meieranalysis [log-rank test]). ResultsWe observed a BRCA1/2 dysfunction rate of 40% (28/70) in high-grade serous tubal/ovarian cancer (HGSC), including14.3% BRCA1 methylation (n=10), 7.1% BRCA1 mutation (n=5), and 18.6% BRCA2 mutation (n=13). Defects inBRCA1/2 genes were associated with stage III/IV HGSC (BRCA1 methylation: P=0.005 [stage III/IV] and P=0.004 [HGSC];BRCA1/2 mutation: P=0.03 [stage III/IV] and P<0.001 [HGSC]). Patients with BRCA1/2-mutated cancers showedimproved OS (hazard ratio [HR], 0.65; 95% confidence interval [CI], 0.43?0.99; P=0.045) and a trend toward improvedPFI (HR, 0.48; 95% CI, 0.22?1.06; P=0.07) and PFS (HR, 0.72; 95% CI, 0.51?1.03; P=0.07). No survival differences wereobserved between BRCA1-methylated and BRCA1/2 wild-type non-BRCA1-methylated cancers. ConclusionWe observed a high tumor BRCA1/2 dysfunction ratein HGSC with a unique predominance of BRCA2 overBRCA1 mutations. While BRCA1/2 mutations conferredsurvival benefits in OC, no such association was observedwith BRCA1 methylation.

목차

등록된 정보가 없습니다.

참고문헌 (35)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0